(2S,4S)-4-(4-(2-acetamidothiazolo[5,4-b]pyridin-5-yl)-1H-1,2,3-triazol-1-yl)-N-(3,4-difluorophenyl)pyrrolidine-2-carboxamide

ID: ALA5196757

Chembl Id: CHEMBL5196757

PubChem CID: 168285956

Max Phase: Preclinical

Molecular Formula: C21H18F2N8O2S

Molecular Weight: 484.49

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)Nc1nc2ccc(-c3cn([C@@H]4CN[C@H](C(=O)Nc5ccc(F)c(F)c5)C4)nn3)nc2s1

Standard InChI:  InChI=1S/C21H18F2N8O2S/c1-10(32)25-21-28-16-5-4-15(27-20(16)34-21)18-9-31(30-29-18)12-7-17(24-8-12)19(33)26-11-2-3-13(22)14(23)6-11/h2-6,9,12,17,24H,7-8H2,1H3,(H,26,33)(H,25,28,32)/t12-,17-/m0/s1

Standard InChI Key:  OOTFJNZUPSBENC-SJCJKPOMSA-N

Alternative Forms

  1. Parent:

    ALA5196757

    ---

Associated Targets(Human)

ABL1 Tclin Bcr/Abl fusion protein (1667 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
K562 (73714 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
K562/Adr (229 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 484.49Molecular Weight (Monoisotopic): 484.1241AlogP: 2.73#Rotatable Bonds: 5
Polar Surface Area: 126.72Molecular Species: BASEHBA: 9HBD: 3
#RO5 Violations: HBA (Lipinski): 10HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 7.95CX Basic pKa: 9.05CX LogP: 1.55CX LogD: 1.05
Aromatic Rings: 4Heavy Atoms: 34QED Weighted: 0.40Np Likeness Score: -2.15

References

1. Pan X, Liu N, Liu Y, Zhang Q, Wang K, Liu X, Zhang J..  (2022)  Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors.,  238  [PMID:35561654] [10.1016/j.ejmech.2022.114425]

Source